medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2021, Number S1

<< Back Next >>

Acta Med 2021; 19 (S1)

COVID-19 and skin manifestations associated with thrombosis and/or microangiopathic phenomena

Poletti VED, Guzmán PMG

Language: Spanish
References: 14
Page: s21-26
PDF size: 221.67 Kb.


ABSTRACT

The SARS-CoV-2 virus disease produces progressive silent hypoxemia. The damage caused by the germ per se, and that mediated by the "immune storm" by inflammatory cells and cytokines, provokes severe devastation of the structure of the pulmonary alveoli, in addition to thrombotic and inflammatory effects, which appear due to cytotoxic and complement activation (vasculitis) and deposition, at the level of the small vessels of the entire economy. This causes severe tissue hypoxia, especially in the acral areas. Cutaneous manifestations range from purpuric lesions, purpura retiform, livedo racemose, cyanosis, and necrosis (gangrene). These manifestations are markers of the severity of the disease and darken the prognosis.


REFERENCES

  1. Sanghvi AR. COVID-19: An overview for dermatologists. Int J Dermatol. 2020; 59 (12): 1437-1449.

  2. Tosti G, Barisani A, Queirolo P, Pennacchioli E, Villa L, Lodeserto AM et al. Skin signs resembling vascular acrosyndromes during the COVID-19 outbreak in Italy. Clin Exp Dermatol. 2020; 45 (6): 757-758.

  3. Mazzotta F, Troccoli T. Acute acro-ischemia in the child at the time of COVID-19. Eur J Pediat Dermatol. 2020; 30 (2): 71-74.

  4. Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, Moreno-Arrones OM, Saceda-Corralo D, Arana-Raja A et al. Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol. 2020; 83 (1): e61-e63.

  5. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020; 382 (17): e38.

  6. Galván Casas C, Catala A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020; 183 (1): 71-77.

  7. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020; 58 (7): 1131-1134.

  8. Gavriilaki E, Brodsky RA. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily. Br J Haematol. 2020; 189 (6): e227-e230.

  9. Song WC, FitzGerald GA. COVID-19, microangiopathy, hemostatic activation, and complement. J Clin Invest. 2020; 130 (8): 3950-3953.

  10. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020; 220: 1-13.

  11. Romaní J, Baselga E, Mitja O, Riera-Martí N, Garbayo P, Vicente A et al. Chilblain and acral purpuric lesions in spain during Covid confinement: retrospective analysis of 12 cases. Actas Dermosifiliogr. 2020; 111 (5): 426-429.

  12. Marraha F, Al Faker I, Gallouj S. A review of the dermatological manifestations of coronavirus disease 2019 (COVID-19). Dermatol Res Pract. 2020; 2020: 9360476. doi: 10.1155/2020/9360476.

  13. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395 (10234): 1417-1418.

  14. Micevic G, Morris J, Lee AI, King BA. Perniolike lesions and coagulopathy in a patient with COVID-19 infection. JAAD Case Rep. 2020; 6 (12): 1294-1296.




2020     |     www.medigraphic.com